XML 47 R20.htm IDEA: XBRL DOCUMENT

OTHER ASSETS

12 Months Ended

Dec. 31, 2024

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

NOTE 10 – OTHER ASSETS

On April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received 10-year warrants to purchase 127,000 shares of Sanuwave Health, Inc. at a price of $0.19 per share. The fair value for warrants received is estimated at the date of grant using a Black-Scholes-Merton pricing model with the following underlying assumptions:

SCHEDULE OF WARRANTS ASSUMPTIONS

	2024			2023
Price at valuation	$	0.01		$	0.01
Exercise price	$	0.19		$	0.19
Risk free interest		3.88	%		3.88	%
Expected term (in years)		7			7
Volatility		147.8	%		147.8	%

The Company considers this to be Level 3 inputs and is valued at each reporting period. As of September 12, 2024, the company terminated the licensing agreement with Sanuwave and recognized $3,000 in gain/loss of termination of investment, offset by change in fair value through the date of termination of $1,000. The fair value of these warrants for the years ended December 31, 2024, and 2023 was $0 and $1,000, respectively. There was a net $3,000 and $2,000 change in fair value during the year ended December 31, 2024, and 2023, respectively.

Financial Liabilities Measured at Fair Value on a Recurring Basis

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

●	Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

●	Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and

●	Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

There were no transfers between Level 3 during the years ended December 31, 2024, and 2023.

The following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2024 and 2023:

	Asset
Balance – December 31, 2022	$	3,000
Fair value adjustments – Sanuwave warrants		(2,000	)
Balance – December 31, 2023	$	1,000
Fair value adjustments – Sanuwave warrants		(1,000	)
Balance – December 31, 2024	$	-

The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy:

Fair Value Measurements as of December 31, 2024

Level I

Level II

Level III

Total

Asset:

Other assets

	Level I		Level II		Level III		Total
	Fair Value Measurements as of December 31, 2023
	Level I		Level II		Level III		Total
Asset:
Other assets	$	-	$	-	$	1,000	$	1,000